4D Molecular Therapeutics, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
B.Riley reiterated a Buy rating and $37.00 price target on 4D Molecular Therapeutics (FDMT), citing trial design and potential for its gene therapy candidate 4D-150. The company's market cap is $791 million, with shares up 91% year-to-date. Analysts highlight strong cash position, upcoming trial readouts, and potential adoption in wet AMD and diabetic macular edema.
Ocular Therapeutix (OCUL) shares dropped 22% as competitors Kodiak Sciences (KOD) and 4D Molecular Therapeutics (FDMT) reported positive updates on their wet AMD treatments. KOD's DAYBREAK study met goals, while FDMT's 4D-150 showed lasting benefits. OCUL's AXPAXLI is in development, with FDA filing planned for late 2026.
4D Molecular Therapeutics, Inc. (FDMT) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 28, 2026, 4D Molecular Therapeutics, Inc. (the “Company”) reported that the first patients have been enrolled across multiple sites in the 4SIGHT Phase 3 clinical trial evaluating 4D-150 for the treatment of diabetic macular edema (“DME”). The
Over the past 7 days, AlphAI's AI scored 1 news story mentioning FDMT (4D Molecular Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent FDMT coverage spans market movers, financial news and insider activity.
In the last 30 days, FDMT insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($833K). The most active reporter was Bizily Scott, Chief Legal Officer, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Analyst coverage upgrade may support short-term price appreciation.
Mixed reaction; stock edged lower despite trial progress.
Positive early trial data may lift the stock as investors anticipate FDA filing.
The insider sale reduces the insider's stake to 767,486 shares, potentially signaling reduced confidence.
Upgrade suggests stronger confidence in FDMT's pipeline and near‑term performance.
AlphAI scores every news story that mentions FDMT with an AI model for sentiment and relevance, and aggregates insider trades from 4D Molecular Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
B.Riley reiterated a Buy rating and $37.00 price target on 4D Molecular Therapeutics (FDMT), citing trial design and potential for its gene therapy candidate 4D-150. The company's market cap is $791 million, with shares up 91% year-to-date. Analysts highlight strong cash position, upcoming trial readouts, and potential adoption in wet AMD and diabetic macular edema.
2 min readOcular Therapeutix (OCUL) shares dropped 22% as competitors Kodiak Sciences (KOD) and 4D Molecular Therapeutics (FDMT) reported positive updates on their wet AMD treatments. KOD's DAYBREAK study met goals, while FDMT's 4D-150 showed lasting benefits. OCUL's AXPAXLI is in development, with FDA filing planned for late 2026.
2 min read4D Molecular Therapeutics, Inc. (FDMT) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 28, 2026, 4D Molecular Therapeutics, Inc. (the “Company”) reported that the first patients have been enrolled across multiple sites in the 4SIGHT Phase 3 clinical trial evaluating 4D-150 for the treatment of diabetic macular edema (“DME”). The
2 min readKirn David (See Remarks) sold 58,333 shares of 4D Molecular Therapeutics, Inc. (FDMT) at $13.90 ($0.81M total) on 2026-09-14 under a Rule 10b5-1 trading plan.
1 min readCompass Point upgraded Coinbase (COIN) to Neutral with a $177 price target, up from $130. Other upgrades include 4D Molecular Therapeutics (FDMT), Affirm (AFRM), Chime Financial (CHYM), and Bullish (BLSH) by their respective analysts. COIN closed at $175.26 on Friday.
2 min readOcular Therapeutix (OCUL) and 4D Molecular (FDMT) shares rose after EyePoint Pharmaceuticals (EYPT) reported its DURAVYU trial missed its primary goal. Clear Street maintained a 'Buy' rating on OCUL, while B. Riley set a $37 target for FDMT. EYPT's stock fell 67% on the news, with OCUL and FDMT gaining 6% and 19% respectively.
2 min readKirn David (See Remarks) sold 69,076 shares of 4D Molecular Therapeutics, Inc. (FDMT) at an average of $15.75 ($15.36–$16.42, $1.09M total) across 2 trades on 2026-08-19 under a Rule 10b5-1 trading plan.
1 min readOcular Therapeutix (OCUL) and 4D Molecular (FDMT) rose after EyePoint Pharmaceuticals (EYPT) said its DURAVYU late-stage wet AMD trial missed its main goal versus Eylea. Analysts cited potential competitive relief for OCUL’s Axpaxli and trial design benefits for FDMT’s 4D-150. OCUL gained 6%, FDMT 19%; EYPT shares fell 67%.
5 min readBiotech gainers were led by 4D Molecular Therapeutics (FDMT), up over 12%, after Phase 3 enrollment progress for 4D-150 in wet AMD and other pipeline updates, plus a $200M credit facility. OmniAb (OABI) rose over 11% on an Eli Lilly collaboration and higher 2026 cash guidance. Acurx (ACXP) gained over 14% after FDA conditional acceptance of CIFBEZY as ibezapolstat’s brand name.
7 min read4D Molecular Therapeutics, Inc. (FDMT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones • Completed enrollment for 4D-150 4FRONT-2 wet AMD Phase 3; topline data expected in H2 2027 • 4D-150 4FRONT-1 Phase 3 topline data expected in Q2 2027 • Prese
6 min read
